A recent court decision has ostensibly made if possible for generic-drug companies to manufacture their own versions of the fish oil pill Lovaza. How does this news affect shareholders of GlaxoSmtihKline (NYSE:GSK), the company that sells the drug in the U.S., and how can this decision affect rivals like struggling biotech company Amarin (NASDAQ:AMRN)?
Analysts David Williamson and Max Macaluso discuss these topics in the following video segment from The Motley Fool's health-care show Market Checkup.
David Williamson owns shares of Amarin. Max Macaluso, Ph.D., has no position in any stocks mentioned. The Motley Fool recommends GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.